Clinical Trials

36 enrolled

Melanoma

NCT03223155 2026-03-04

COSINR

78 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

18 enrolled

Sarcoma

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05536141 2026-02-27

ARC-20

362 enrolled

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07401875 2026-02-27

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

35 enrolled

Kidney Neoplasms

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT03600155 2026-02-17

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03233139 2026-02-12

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

146 enrolled

Advanced Malignancies

NCT00586391 2026-02-06

CRETI-NH

LymphoidOther hematologic neoplasm

14 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02950766 2026-02-03

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

19 enrolled

Kidney Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

39 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

GastrointestinalSarcomaThoracic

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

NCT06968988 2026-01-08

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

18 enrolled

Sarcoma

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT03245892 2025-12-17

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

27 enrolled

Gynecologic

High Grade Serous Ovarian

NCT06049576 2025-12-17

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Phase 1 Suspended

30 enrolled

Carcinoma, Renal Cell

NCT06889493 2025-12-17

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

36 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04117087 2025-12-03

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

27 enrolled

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04248569 2025-12-03

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

56 enrolled

Fibrolamellar hepatocellular carcinoma

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

9 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04388852 2025-11-21

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

65 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

26 enrolled

Carcinoma, Renal Cell

NCT07075120 2025-10-28

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

15 enrolled

Carcinoma, Hepatocellular

NCT02668770 2025-10-23

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

28 enrolled

Melanoma, Neoplasm Metastasis, Recurrence

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Phase 1 Terminated

67 enrolled

Uveal Melanoma

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma